For pharmaceuticals ranging from Digitalis to vincristine, the ethnobotanical approach to drug discovery has proven successful. The value of ethnobotanical information in drug development is based on several factors, which are discussed. Published ethnomedical information has many strengths and weaknesses relative to the ability to establish a corresponding biological effect in the laboratory. The ability to correlate ethnomedical reports with corresponding scientific studies could lead to improved selection of plants for further scientific studies. The application of NAPRALERT database in this regard is also discussed. An elaborate plant to drug pathway has been traced out for young researchers to make the drug discovery pathway more approachable. Various cautions related to possible errors during the ethnobotanical approach have also been highlighted.
Bioactive natural products have an enormous economic importance as value added and life saving chemicals. They can be used as drugs, lead compounds, biological or pharmacological tools, and as raw materials for the production of drugs and nutraceuticals [1] . Natural products have been an overwhelming success in our society. They have reduced pain and suffering, and revolutionized medicine by facilitating the transplantation of organs. Natural products are the most important anticancer and anti-infective agents. More than 60% of approved and pre-new drug application (NDA) candidates are either natural products or related to them, not including biologicals such as vaccines and monoclonal antibodies [1] . In the battle for survival, plants have developed many chemical defenses to ward off attackers, such as bacteria, insects, fungi, and in some cases mammals, that may threaten the survival of a species. While not essential for growth, these secondary metabolites do promote the spread and dominance of a species in an ecological setting, and are therefore worth the energy expended by the plant to produce them. It is the secondary metabolites of plants in bio-diverse regions that invite the interest of pharmacognocists seeking new lead compounds from folk medicines. Nature has been continually carrying out its own version of combinatorial chemistry for over 3 billion years, at a time when only bacteria inhabited the earth [2] . During that time, there has been an evolutionary process which made the producers of secondary metabolites evolve according to their then existing local environments. If the metabolites were useful to the organism, the biosynthetic genes were retained, and genetic modifications further improved the process. Combinatorial chemistry practiced by Nature is much more sophisticated than that in the laboratory, yielding exotic stereochemically rich structures, concatenated rings, and reactive functional groups. As a result, an amazing variety and number of products have been found in Nature. The process of drug discovery, no matter how approached, is generally recognized as a high risk/high pay-off endeavor. Henceforth, through this review article we make an attempt to dig the roots of secrets of drug discovery from traditional knowledge using an ethnobotanical prospective, for highlighting different strengths and challenges involved in the process which may make the drug discovery path more approachable.
Rationale behind ethnobotanical approach to drug discovery: It is thought that about 80% of the 5200 million people of the world live in less developed countries. The world Health Organization estimates that about 80% of these people rely almost exclusively on traditional medicine for their primary health care needs [3] . Since medicinal plants are the 'backbone' of traditional medicine, this indicates that more than 3300 million people in the less developed countries utilize medicinal plants on a regular basis. Thus, for this segment of the world population, who are generally unable to pay the cost of so called 'Western drugs', there is need to study these plants for safety and efficacy and to develop globally acceptable and standardized products. The major thrust from a scientific point of view is to find biologically active molecules with the intent of altering the structures in an attempt to either enhance activity or decrease toxicity. Such molecules will then be strong lead candidates. Thus all these facts make it extremely important to know the roots of the process which thus ultimately form the basis of ethnobotanical study.
Ethnobotany is a broad term referring to the study of plants by humans. This includes plants used as foods, medicines, building materials and for any other economic importance. Ethnomedicine refers to the use of plants by humans as medicines, but probably should be called ethnobotanical medicine [4] . Traditional medicine is the sum total of all non-mainstream medical practices, usually excluding so-called 'Western' medicine. Generally speaking, plants used in various forms of traditional medicine have different potential medicinal values, according to the degree of authentication of the medical practice involved. For example, traditional Chinese, Ayurvedic, and Unani medical systems are all based on a theory (belief may vary), formal education and a written documented history. The systems are periodically revised on the basis of experience and current thought. Information on plants used in these systems is probably more reliable than that from other systems, such as traditional healers, 'witch doctors' and herbalist. In these practices, the apprentice system is practiced, whereby information is passed on from person to person, father to son, guru to disciple. There is usually no formal educational component to these systems and frequently the information is considered highly secretive and is not documented in writing. In spite of the skepticism of Western trained physicians and scientists concerning the value of information resulting from any of these systems, all together they are currently serving the primary health care needs of most of the world's population and this source must not be ignored in any program of rational drug development, starting with plant materials.
Ethnobotany and drug discovery: Historically, ethnobotanical leads have resulted in three different types of drug discovery: (1) unmodified natural plant products where ethnomedical use suggested clinical efficacy (like digitaline); (2) unmodified natural products of which the therapeutic efficacy was only remotely suggested by indigenous plant use (like vincristine); and (3) modified natural or synthetic substances based on a natural product used in folk medicine (like aspirin). The ethnobotanical drug discovery programs follow the general sequence: (1) folk knowledge accumulates concerning possible medicinal activity of a plant; (2) the plant is used therapeutically by a healer; (3) the healer communicates this knowledge to a researcher (pharmacognocist); (4) the researcher collects and identifies the plant; (5) plant extracts are tested using a bioassay; (6) bioassay-guided fractionation leads to isolation of an active substance; and (7) the structure of the pure substance is determined.
Plant to drug-the pathway: When screening for biologically active plant constituents, the selection of the plant species to be studied is obviously a crucial factor for the ultimate success of the investigation. There are two main strategies used for the selection of plant species: random screening and ethnobotany. With over 500,000 plant species on Earth, and each of these having leaves, bark and roots with different phytochemical composition, as well as seasonal and geographical variations in the phytochemistry of many plant species, the likelihood of finding an active plant sample from a random screening survey is fairly small and challenging [5] . It is even less likely that the active compound isolated from the plant sample is novel or has a novel mode of action that is more efficient than any product currently on the market. These problems can often be overcome by using ethnobotany to investigate those species that have been traditionally used as medicines for many generations. Traditional knowledge includes details such as the season during which a particular plant species produces biologically active compounds, which part of the plant contains this biological activity, and the particular region (such as altitude) in which a species is more active. As a result of their long term use, traditional medicines, including folklore remedies, are generally considered to be safe and medically suitable, and as such have proven to be a reliable source of active compounds. This approach forms the basis of "Reverse Pharmacology" coupled drug discovery [6] . According to this approach, as the starting material is based upon a strong ethnobotanical lead so the probability of ending up with a bioactive compound is at the maximum, which is just the reverse in the case of a synthetic chemistry approach. Large scale studies investigating the potential of medicinal plants have reported a high correlation between the traditional use of plants and the presence of active compounds within the plant extract [7] . Screening the crude extract of medicinal plants determines the presence of biologically active compounds, and therefore validates the use of such plants in traditional medicines. Initial screening of plant extracts often involves antimicrobial testing, regardless of the use of the medicinal plant, since this testing is fast, ethical, and relatively inexpensive. Antimicrobial screening involves simply exposing the target organism (bacteria, fungi, viruses, or parasites) to the extracted plant material, and observing the presence or absence of growth after exposure. This is a useful technique that quickly determines if the plant extract should undergo further investigation [8] . However, selection of plants based on a chemotaxonomic approach is also commonly followed. In this case, if one knows that a certain class of chemical compounds is more promising biologically for an activity of interest than other classes, one can select plants that are predicted to contain that particular class using principles of chemotaxonomy. Use of NAPRALERT (Natural Products ALERT) is also one common strategy for the selection of a plant [9] . One can laboriously scan the literature for plants that have been reported to produce a biological activity of interest and also have an ethnomedical claim for the same use. Further literature searching would reveal whether or not any chemical compounds had been isolated from the plants that were responsible for the desired effect. NAPRALERT contains a huge database on ethnomedical information on the uses of plants, the secondary metabolites and the biological effects reported for these secondary metabolites. In a NAPRALERT analysis, the database is first searched for plants whose extracts have shown a desired activity, for example, for diabetes. These are sorted and saved in group A. Group B represents all plants that contain secondary metabolites reported to have antidiabetic activity. Group C represents plants that have ethnomedical claims associated with diabetes. After the database merges these, two lists of plants emerge as priorities for drug development. The 'D' plants are those that have an ethnomedical reputation as being used for diabetes, which have been shown experimentally to have antidiabetic activity and which contain no compounds that can explain the antidiabetic effects. The 'E' plants are those which have ethnomedical claims for diabetes, which also have been shown experimentally to have antidiabetic effects and which also contain one or more compounds reported to have antidiabetic effects. Thus, the 'D' plants are those which are of interest to a scientist who wants to identify bioactive(s), hopefully novel, which can be developed as potential drug candidates. The 'E' plants are those that could be suitable for use in less developed countries where all ethnomedical and experimental evidence suggests efficacy and which contain active compounds that could serve as markers for use in quality control procedures in galenical preparations [10] .
The classical process leading from a bioactive extract to a pharmacologically active pure constituent has always been a long and tedious process requiring substantial material amount and financial resources. It consists of several consecutive steps of preparative chromatographic separation, whereby each fraction has to be submitted to suitable bioassays to track the activity ultimately to a defined pure compound [11] . While this procedure has led to the successful isolation of many bioactive molecules in the past, its weakness cannot be overlooked. Besides being slow and costly, the separation performance is poor, at least in the initial fractionation steps which are typically by open column chromatography. The loss of bioactivity in the course of the purification process is not uncommon and there is little means for early dereplication of known or otherwise uninteresting compounds. The approach described above hardly matches the timelines and the workflow of modern drug discovery. In the past decade, more effective strategies have been developed that are adequate for a high throughput environment. The concerted use of HPLC-DAD, MS and NMR has opened entirely new possibilities for the characterization of secondary metabolites in biological extracts by providing a wealth of structural information online with minute amounts of sample [12] . Even absolute configuration can also be established using tandem spectroscopy techniques. With the more recent emergence of mass spectrometry controlled preparative high performance liquid chromatography (HPLC), compound purification has also become straightforward, provided the compounds are sufficiently Ethnobotanical route to drug discovery Natural Product Communications Vol. 7 (11) 2012 1553 stable. The developments in the field of nuclear magnetic resonance (NMR), in particular the advent of new probe technology and higher magnetic fields, as well as the miniaturization process in crystallography has rendered structural elucidation of amounts of less than a milligram a rather routine process [13] . While analysis, purification and structure elucidation of natural products have experienced a technological breakthrough over the last decade, tracking bioactivity in complex matrices such as plant extracts remains a highly challenging task. The most common problem encountered in the detection of pharmacological activity is that even extracts from single plants are a mixture of several compounds which can be subject to variation in concentration or composition according to ecological changes. Traditional remedies seldom conceal a single active constituent, and in many cases the therapeutic benefits are attributed to the consumption of plant mixtures in which whole plants or plant parts are prepared and/or consumed in combination or in sequence [14] . This complicates the pharmacological investigation of such preparations, since determining which of the many constituents of a single plant is active requires much work, and this is compounded by the presence of constituents from several plants. This is found particularly where medicinal plants show less specific activity. Some plants may be added to reduce the toxicity of the more therapeutically effective plants [11] . The effects of drug interactions in medicinal preparations are largely unknown since a therapeutic profile on each constituent would be required. Some pharmacological studies have been initiated on multi-drug preparations, revealing significant interactions. In the case of higher plant extracts, the majority of false positives can be attributed to the presence of polyphenols, detergents such as saponins and certain pigments or fatty acids. Phenols affect highly purified enzyme-based targets, while saponins primarily disrupt membranes in cellular targets or dislodge substrates absorbed onto assay wells. Pigments tend to interfere with read-outs in colorimetric or quenched assays. Fatty acids show activity through a variety of mechanisms. The removal of these undesirable compounds from the plant extract henceforth becomes essential before the primary screening process [15] . Even where a purified extract or synthetic analogue is identified, there is the possibility that some of the apparently pharmacologically inert constituents could have important effects with respect to the administration of the drug. The administration of digitaline in Western medicine requires temporary interruptions to avoid dangerous accumulations of this drug. In contrast, such precautions are unnecessary in the ethnomedical use of the whole Digitalis plant, suggesting an interaction of the active principle with other constituents in the plant. Existing assays can not necessarily reliably predict clinical efficacy, and suitable pharmacological models have not yet been developed for many common diseases with unknown or multifactorial origins. The lack of a positive result in a screening assay does not always mean the absence of bioactive constituents. The active principle(s) may be present in insufficient quantities in the crude extracts to show activity in the dose levels employed. Lack of activity can thus only be proven by using large doses [11] . Alternatively, if the active principle is present in high enough quantities, there could be other constituents exerting antagonistic effects or nullifying the positive effects of the active principles during the assay. Fractionation of the extracts before screening by partitioning or serial extraction, can in some cases overcome this problem, although this multiplies the number of samples to be tested. In vitro screening methods have a further inherent problem in that some compounds showing good activity in an in vitro assay may be metabolized in vivo into inactive metabolites. Conversely, some extracts show only in vivo activity due to the metabolism of inactive compounds into active forms. Once an extract has shown promising activity in the screening tests, fractionation and purification procedures are conducted in order to isolate the active principle. Firstly, the procedures employed must be effective and appropriate to isolate and separate the active compounds. Even using bioassay-guided fractionation, there is a real possibility of loss of activity. This can be caused by the compound in question being labile (sensitive to temperature, light, acidity, basicity or the extracting solvent) and consequently it is progressively degraded during fractionation. Alternatively, some compounds are inactive in situ but act synergistically with other constituents of the extract. Separation into different fractions during purification will thus result in a decrease or total loss in activity in all the fractions. The activity of some compounds is dose dependent, causing different or antagonistic activity with the increase in concentration brought about by the fractionation procedures. This can be overcome by adjusting the dose levels to be assayed at progressive stages. In addition, minor compounds in the crude extracts may become concentrated in later fractions and exhibit unexpected biological activity. The duplication of pharmacological results is important. Failure to do so could result from a variation in the concentration of active compounds due to environmental or genetic factors [15] . These include the season, area of collection, physiological age of the plant, and physiological state (e.g. flowering). Genetic variation (genotype) usually causes qualitative differences in different samples, while the environmental factors usually affect quantitative results. Another cause is the failure to collect the same specimen on separate occasions, which emphasizes the importance of voucher specimens. Initial thin layer chromatographic (TLC) profiles or fingerprints of active extracts, as well as the subsequent active fractions, should be performed and filed before the active principle(s) are isolated and identified to enable comparison between samples. However, in many cases the tests used to screen herbal remedies are inadequate, largely as a result of the complex nature of these preparations. Pharmacological tests need to be tailored to fully evaluate traditional remedies.
Challenges of ethnobotanical approach:
Botanists who conduct field work in areas where use of medicinal plants is a way of life are not trained to fully understand the disease state. The information gathered is generally inadequate for the laboratory scientist to evaluate in terms of selecting plants for expensive biological investigations. For example, the literature in ethnobotany, ethnomedicine and ethnopharmacology usually documents the following information: (a) the Latin binomial of the plant used, (b) common or local names of the plant used, (c) plant part and (d) geographical area where used. Data that are required in an ethnobotanical writing for assessment of the value of the plant medicine are (a) method of preparation of the medicine, (b) dosing, (c) source of information (which if not mentioned is difficult to trace), (d) route of administration and the symptomology of the disease. There are numerous examples that might be cited of these deficiencies; the following should make the point. If ethnobotanical information states that a plant is used to allay thirst and since thirst is one of the many symptoms of diabetes, follow-up questions should be asked to see if the user urinates frequently, is susceptible to fungal infections or has any other characteristic symptoms of diabetes. While dealing with the use of a plant as 'contraceptive', rarely does the literature indicate whether the plant is taken by men, women or both. If taken by women, questions regarding the fertility of the woman, the age, sexual activity and menstrual patterns should be recorded.
Users of traditional medicines often perceive a relationship between the shape, color and odor of plant materials and features of their diseases. This prompted the use of such plants for afflictions related to these factors. This is known as the doctrine of signatures. Some examples might be that a plant which exudes a red sap or resin, or plants that are red in color, may be useful for hemorrhages, for menstrual or blood related disorders. Also, plants that have a serpentine root system may be useful for snakebite and those with white latex able to increase male fertility or supply milk in lactating women [16] . However, in the course of time, some plants chosen might quite by chance have been useful for the intended purpose. However, on the basis of scientific experience, one should avoid selecting plants for scientific study that have obvious relationship to the doctrine of signatures. The point is that if ethnomedical information is to be of value in drug discovery, it must be collected in more detail. Otherwise, this approach is no better than random selection followed by targeted biological screening. However, development of ethnobotanically trained personnel through inclusion of this subject in the pharmacy curriculum can solve the problem to a great extent. Moreover, evaluations of the relative efficacy of ethno-directed sampling in relation to specific drug types predict that properly designed ethnobotanical surveys could prove more successful in identifying drugs from specific plants used in the treatment of gastrointestinal, inflammatory and dermatological complaints, than, for example, of cancer .
Conclusion:
The sciences of ethnobotany and ethnomedicine are developing rapidly due to the recent improvements in screening techniques, including in vitro bioassays. In the past, analysis of plants has not successfully isolated the active components because the assays lacked sufficient sensitivity. Current tests could prove successful where negative results were obtained 20 years ago. With the development of more selective in vitro assays, the quantities of plant material that need to be collected and stored has dropped from 5-10 kg to 50-500 g. This obviously has important ecological implications. In addition, conservation trends have been extended to the collection of different plant parts, with greater emphasis placed on sustainable harvest, like bark is not collected if this would endanger the survival of the tree, and limited amounts of root systems are harvested. The evaluation and authentication of traditional remedies can contribute towards the formulation of an integrated health care system combining both local and Western practices. This involves the documentation and testing of the efficacy and toxicity of medicinal plant extracts, and the identification of the active principles. This would enable local knowledge of medicinal plants to be compiled and conserved, and recommendations for usage to be based on an empirical understanding of the activity and toxicity. Numerous publications describing novel natural products and biologically active principles from assay results have for many years formed the basis for pharmacognostical research. With application of emerging techniques and integration of informatics, entirely novel possibilities for rational selection, prediction, and interpretation are within grasp. With this comes, obviously, a need for popularizing the study of pharmacognosy with a modern approach coupled with practical application needs to be thought of seriously with proper information flow and best utilization of available resources.
Hopefully, readers of this review will obtain an inside view towards the roots of drug discovery and how to approach it. A recently published excellent review also gives a full view of the applicability of herbal medicine in health care [17] . It can be believed that both the articles will provide a vivid description of the journey from traditional medicine (ethnopharmacology) to modern medicine.
